Home Polymorphisms of the peroxisome proliferator-activated receptor-γ coactivator-1α gene are associated with hypertrophic cardiomyopathy and not with hypertension hypertrophy
Article
Licensed
Unlicensed Requires Authentication

Polymorphisms of the peroxisome proliferator-activated receptor-γ coactivator-1α gene are associated with hypertrophic cardiomyopathy and not with hypertension hypertrophy

  • Shuxia Wang , Chunyan Fu , Hu Wang , Yi Shi , Xiqi Xu , Jingzhou Chen , Xiaodong Song , Kai Sun , Jianwei Wang , Xiaohan Fan , Hongjian Wang , Xiaomin Yang , Tujun Huan and Rutai Hui
Published/Copyright: August 9, 2007
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 45 Issue 8

Abstract

Background: The clinical phenotype of both hypertrophic cardiomyopathy (HCM) and left ventricular hypertrophy (LVH) induced by hypertension is heterogeneous. Genetic factors may contribute to this heterogeneity. Evidence is accumulating that the peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) gene plays a role in cardiac hypertrophy. The aim of our study was to identify the association between PGC-1α gene polymorphisms and cardiac hypertrophy.

Methods: A total of 270 consecutive HCM patients and 2486 hypertensive patients, comprising 1180 with LVH and 1306 without LVH, as well as 894 healthy controls, were successfully investigated. Polymorphisms of the PGC-1α gene were genotyped by PCR-restriction fragment length polymorphism and confirmed by sequencing.

Results: The Ser482 allele (rs8192678 G>A and A>A) and CC genotype of Thr394Thr (rs2970847) conferred increased risk for HCM [odds ratio (OR) 1.52, 95% confidence interval (CI) 1.11–2.11; OR 1.49, 95% CI 1.15–1.98, respectively]. The maximum ventricular thickness was greater in HCM patients carrying the Ser482 risk allele than in carriers of the non-risk allele (20.7±4.1 vs. 19.1±4.3 mm, p<0.05) and for the CC Thr394Thr genotype (20.9±4.6 vs. 19.0±4.2 mm, p<0.05). No association was found between PGC-1α polymorphism and hypertension with or without LVH.

Conclusions: Our data indicate that variants of the PGC-1α gene are correlated with increased risk for HCM.

Clin Chem Lab Med 2007;45:962–7.


Corresponding author: Rutai Hui, MD, PhD, Sino-German Laboratory for Molecular Medicine, Key Laboratory for Clinical Cardiovascular Genetics of Ministry of Education, and Hypertension Division, Department of Cardiology, Cardiovascular Institute & FuWai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 167 Beilishi Road, Beijing 100037, PR China Phone: +86-10-68333902, Fax: +86-10-68331730,

Received: 2007-2-13
Accepted: 2007-4-18
Published Online: 2007-08-09
Published in Print: 2007-08-01

©2007 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Congress of Clinical Chemistry and Laboratory Medicine, Joint Annual Congress of The Austrian Society for Laboratory Medicine and Clinical Chemistry (OEGLMKC) and the The German United Society of Clinical Chemistry and Laboratory Medicine (DGKL), Vienna, Austria, September 19-22, 2007
  2. Interpretation of laboratory results: the Reference Intervals, a necessary evil?
  3. Implementation of haemoglobin A1c results traceable to the IFCC reference system: the way forward
  4. Exhaled breath condensate: a new method for lung disease diagnosis
  5. Biochemical markers of alcoholism
  6. Polymorphisms of the peroxisome proliferator-activated receptor-γ coactivator-1α gene are associated with hypertrophic cardiomyopathy and not with hypertension hypertrophy
  7. Association of interleukin-1 genetic polymorphisms with the risk of rheumatoid arthritis in Chinese population
  8. Highest accuracy of combined consensus clinical criteria and SNRPN gene molecular markers in diagnosis of Prader-Willi syndrome in Thai patients
  9. Use of maternal plasma for non-invasive prenatal diagnosis of fetal ABO genotypes
  10. Relationship of the CAG repeat polymorphism of the MEF2A gene and coronary artery disease in a Chinese population
  11. Specific real-time PCR vs. fluorescent dyes for serum free DNA quantification
  12. Increased glycation of hemoglobin and plasma proteins in normotensive, non-diabetic obese Indian subjects: putative role of lipid peroxides
  13. The relationship between red blood cell and reticulocyte indices and serum markers of iron status in the cord blood of newborns
  14. Association of amino-terminal propeptide of type III procollagen and acute myocardial rejection in male patients receiving heart transplantation
  15. Changes in platelet count and indices in pulmonary tuberculosis
  16. Activity or mass concentration of bone-specific alkaline phosphatase as a marker of bone formation
  17. A simple isocratic HPLC assay to determine linezolid concentrations in different biomatrices for in vivo and in vitro studies
  18. Pitfalls in measuring the endocannabinoid 2-arachidonoyl glycerol in biological samples
  19. Partitioning reference values for several subpopulations using cluster analysis
  20. A plea for intra-laboratory reference limits. Part 1. General considerations and concepts for determination
  21. A plea for intra-laboratory reference limits. Part 2. A bimodal retrospective concept for determining reference limits from intra-laboratory databases demonstrated by catalytic activity concentrations of enzymes
  22. Biological variation of thyroid autoantibodies and thyroglobulin
  23. Monitoring glycaemic control: is there evidence for appropriate use of routine measurement of glycated haemoglobin?
  24. Performance and utility of a cost-effective collagen-binding assay for the laboratory diagnosis of Von Willebrand disease
  25. Hook effect in calcitonin immunoradiometric assay
  26. Rapid genotyping of the Ser447Stop variant of the lipoprotein lipase gene using real-time fluorescent PCR
  27. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group
  28. Recommendation for term and measurement unit for “HbA1c”
  29. Desirable performance standards for HbA1c analysis – precision, accuracy and standardisation Consensus statement of the Australasian Association of Clinical Biochemists (AACB), the Australian Diabetes Society (ADS), the Royal College of Pathologists of Australasia (RCPA), Endocrine Society of Australia (ESA), and the Australian Diabetes Educators Association (ADEA)
  30. IFCC Position Paper: Report of the IFCC Taskforce on Ethics: Introduction and framework
  31. IFCC Awards: Call for Nominations
  32. Call for papers, ideas and initiatives
Downloaded on 20.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2007.189/html
Scroll to top button